Welcome to our dedicated page for Sol Gel Tech SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sol-Gel Technologies Ltd.'s SEC filings document the disclosure record of a foreign private issuer developing and partnering dermatology drug products. Form 6-K reports include operating and financial results, unaudited condensed financial statements, clinical and regulatory updates for SGT-610, SGT-210 and EPSOLAY, and material-event disclosures incorporated by reference into the company's Form S-8 and Form F-3 registration statements.
The filings also cover shareholder meeting materials, auditor appointments, board elections, interim executive leadership approvals under Israeli corporate governance requirements, and capital-structure matters involving the company's ordinary shares. These documents frame Sol-Gel's public-company reporting around dermatology pipeline development, approved topical products, licensing arrangements, governance actions, and financing capacity.
Sol-Gel Technologies Ltd. furnished a Notice of its 2025 Annual General Meeting and an accompanying proxy statement, together with a proxy card for shareholders of record as of September 29, 2025. The materials are incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, ensuring the proxy disclosures are available to holders eligible to vote and to support related securities registrations. This filing supplies the formal voting materials shareholders need to review meeting matters and to submit proxies ahead of the meeting.
Sol-Gel Technologies Ltd. filed a report noting that it has received Health Canada approval for EPSOLAY®. This approval, announced in a company press release, represents official clearance for the product in the Canadian market. The filing also states that portions of the press release are incorporated by reference into Sol-Gel’s existing registration statements on Form S-8 and Form F-3, linking the product approval to the company’s broader capital markets documentation.
Opaleye Management Inc., Opaleye, L.P. and James Silverman reported beneficial ownership of 139,386 ordinary shares of Sol-Gel Technologies Ltd (SLGL), representing 5.00% of the class based on 2,785,787 shares outstanding. The shares are held by the Fund with voting and dispositive power shared among the reporting persons; no sole voting or dispositive power is reported. The filing states the stake was not acquired to change or influence control of the issuer and includes a joint filing agreement signed by James Silverman.
Sol-Gel Technologies Ltd. submitted a Form 6-K reporting two exhibits: a press release dated August 15, 2025 and unaudited condensed consolidated financial statements as of June 30, 2025 covering the three- and six-month periods ended June 30, 2025. The filing amends and restates the incorporation-by-reference language so that Exhibit 99.1 (except for four paragraphs immediately preceding the financial-results heading) and Exhibit 99.2 are incorporated into the company’s registration statements on Forms S-8 and F-3. The report is signed by the Chief Financial Officer, indicating the exhibits are being furnished to the SEC and made available to investors and registrants relying on the referenced registration statements.